Influence of Admission Blood Glucose in Predicting Outcome in Patients With Spontaneous Intracerebral Hematoma

Lakshman I. Kongwad, Ajay Hegde*, Girish Menon and Rajesh Nair

Department of Neurosurgery, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, India

Background and Aims: Hyperglycemia or elevated blood glucose levels have been associated with poor outcomes in patients with ischemic stroke yet control of hyperglycemia has not resulted in good outcomes. High admission blood glucose (ABG) values have been mitigated by other poor prognosticators like large hematoma volume, intraventricular extension (IVE) of hematoma and poor GCS. The aim of this study was to evaluate the effects of blood glucose levels at admission, on mortality and functional outcomes at discharge and 3 months follow up.

Methods: This was a retrospective observational study conducted at a tertiary care. Patients with spontaneous SICH were enrolled from a prospective SICH register maintained at our hospital. Blood glucose values were recorded on admission. Patients with traumatic hematomas, vascular malformations, aneurysms, and coagulation abnormalities were excluded from our study.

Results: A total of 510 patients were included in the study. We dichotomised our cohort into two groups, group A with ABG > 160 mg/dl and group B with ABG < 160 mg/dl. Mean blood glucose levels in these two groups were 220.73 mg/dl and 124.37 mg/dl respectively, with group A having twice the mortality. mRS at discharge and 3 months was better in Group B (p ≤ 0.001) as compared to Group A. Age, GCS, volume of hematoma, ABG, IVE and Hydrocephalus were significant predictors of mortality and poor outcome on univariate analysis with a p < 0.05. The relationship between ABG and mortality (P = 0.249, 95% CI 0.948–1.006) and outcome (P = 0.538, 95% CI 0.997–1.005) failed to reach statistical significance on multivariate logistic regression. Age, Volume of hematoma and GCS were stronger predictors of mortality and morbidity.

Conclusion: Admission blood glucose levels was not an independent predictor of mortality in our study when adjusted with age, GCS, and hematoma volume. The effect of high ABG on SICH outcome is probably multifactorial and warrants further research.

Keywords: intracerebral hemorrhage, mRS, stroke, admission blood glucose, stroke outcome
INTRODUCTION

Spontaneous Intracerebral Hemorrhage (SICH) accounts for 15 to 20% (1, 2) of all strokes encountered in a tertiary care hospital and is associated with higher mortality and morbidity when compared with ischemic strokes (3, 4). Stress hyperglycemia is associated with a high risk of mortality after both stroke (5) and myocardial infarction (6). Hyperglycemia at the time of stroke has been associated with poor prognosis in ischemic stroke (7, 8).

However in ICH, literature shows conflicting results with few studies showing that high blood glucose could have a biologically plausible association with poor outcomes and death (9–17).

High blood glucose level is related to brain edema and neuronal apoptosis in ICH (18). Hyperglycemia is also reported to promote blood-brain barrier destruction via downregulation of Aquaporin-4 channels (19). Studies have shown that patients with elevated admission blood glucose (ABG) levels were associated with an increased incidence of cerebral complications and more widespread bleeding, re-bleeding, brain oedema, and poor functional outcome at the time of discharge (20).

However the association is still controversial whether admission hyperglycemia independently affects outcomes or is associated with other prognostically poor features of stroke (8, 12, 21–23).

In this study we aim (a) to evaluate if ABG levels can be an independent predictor of mortality and outcome and (b) to correlate the values of blood glucose with other predictors of mortality and outcome in our cohort.

MATERIALS AND METHODS

This was a retrospective observational study conducted at Kasturba Hospital Manipal, a tertiary care center in the small coastal town in of Udupi, Karnataka, India. All consecutive patients with spontaneous SICH from February 2015 to July 2017 were enrolled in our study from a prospective SICH register maintained at our hospital. Data pertaining to age, sex, hypertension, diabetes, admission systolic, and diastolic blood pressures, admission glucose level, Glasgow Coma Scale (GCS) score, volume of hematoma, presence of intraventricular hemorrhage, hydrocephalus were collected from the database.

Patients with traumatic hematomas, vascular malformations, aneurysms, and coagulation abnormalities were excluded from our study. Hematoma volume was calculated by the (abc)/2 method (24, 25) on 5 mm slices of non-contrast CT on admission. Admission blood glucose values were recorded from venous sample by Hexokinase method on admission. Modified Rankin scale (mRS) was used to assess outcome at discharge and at 3 months follow up. Telephone assessment mRS, shown to have good inter-rater reliability was used for patients who did not present to the clinic at 3 months (26). Patients with mRS of 0–3 were classified as good outcome and 4–6 as poor outcome. Mortality was tabulated with the mRS available at 90 days.

Statistical Analysis

The primary outcome determinants considered were mortality and outcome, as measured using mRS at discharge and 3 months. Analysis was performed using IBM SPSS V24 and R V 3.4.1 for Macintosh. Descriptive statistics included mean, median and standard deviation. Continuous variables were analyzed using Student t-test for normally distributed data and Mann-Whitney test for skewed data. Categorical variables were analyzed with Chi Square test. Pearson correlation coefficient was used to determine correlation between continuous variables. At multivariate level, logistic regression analysis was used to determine variables associated with mortality and poor functional outcome. Variables with $p < 0.05$ at univariate level were included in multivariate modeling. Outcomes were reported as odds ratios (OR) with 95% confidence interval (CI). ROC curve analysis was performed for blood glucose value to determine cut-off levels that predicted death. A $p$-value of $<0.05$ was considered significant.

RESULTS

A total of 510 patients were analyzed in our study. The mean age of our study group was 58.39 years with a range of 23–93 years. One hundred forty-six patients (28.62%) were below the age of 50 years with predominantly males (M:F:363:147). Five patients were excluded from our analysis as ABG was not available.

We dichotomized our cohort into 2 groups, Group A and Group B, based on admission blood glucose. ROC curve was used to determine the midpoint of the curve (Figure 1) and patients with ABG >160 mg/dl were categorized as Group A and ABG <160 mg/dl as Group B (Table 1). Though the mean age seemed to be identical in both the cohorts there was a striking male preponderance (Group A M:F; 126:51, Group B M:F; 234:94).
TABLE 1 | Demographic, clinical, radiological, and outcome of our dichotomized cohort.

| Parameter                      | GRBS > 160 (n = 177) | GRBS ≤ 160 (n = 328) | p   |
|--------------------------------|-----------------------|----------------------|-----|
| **DEMOGRAPHICS AND RISK FACTORS** |                       |                      |     |
| Age (years)                    | 58.37 ± 12.99         | 58.42 ± 12.32        | 0.96|
| Male                           | 126 (35%)             | 234 (65%)            |     |
| Female                         | 51 (35.2%)            | 94 (64.8%)           |     |
| Hypertension                   | 106 (39.8%)           | 160 (60.2%)          | 0.011|
| Duration in years              | 5.7 ± 4.81            | 4.7 ± 4.7            |     |
| Diabetics                      | 36 (25.9%)            | 103 (74.1%)          | 0.006|
| Duration in years              | 8.9 ± 5.98            | 5.39 ± 4.16          |     |
| Smoking                        | 47 (48.4%)            | 50 (51.6%)           |     |
| Alcohol                        | 69 (37.5%)            | 115 (62.5%)          | 0.244|
| **CLINICAL FEATURES**          |                       |                      |     |
| Heart rate (bpm)               | 84.7 ± 18.24          | 82 ± 16.98           |     |
| Systolic BP (mmHg)             | 184.29 ± 29.51        | 171.34 ± 27.56       | <0.001|
| Diastolic BP (mmHg)            | 103.33 ± 13.76        | 99.1 ± 12.83         | 0.001|
| GCS (median)                   | 11                    | 12                   |     |
| GCS < 8                        | 67 (64.9%)            | 55 (45.1%)           | 0.001|
| ICH score (median)             | 2                     | 1                    | <0.001|
| Blood glucose (mg/dl)          | 220.73 ± 57.23        | 124.37 ± 20.05       | <0.001|
| Supratentorial hemorrhage       | 146                   | 298                  |     |
| Volume (ml)                    | 31.54 ± 23.12         | 19.55 ± 13.77        | <0.001|
| >30 ml                         | 72                    | 61                   | <0.001|
| Infratentorial hemorrhage       | 31                    | 30                   |     |
| IVE                            | 109 (47.6%)           | 120 (52.4%)          | <0.001|
| Hydrocephalus                  | 57 (45.6%)            | 68 (54.4%)           | 0.003|
| Hematoma growth                | 9 (39.1%)             | 14 (60.9%)           | 0.36 |
| EVD                            | 17 (47.2%)            | 19 (52.8%)           | 0.081|
| Surgery                        | 45 (63.6%)            | 39 (46.4%)           | <0.001|
| **OUTCOME**                    |                       |                      |     |
| MRS at discharge               | 5                     | 4                    | <0.001|
| MRS at 3 months                | 5                     | 3                    | <0.001|
| MRS 0–3                        | 63 (26.5%)            | 174 (73.5%)          | <0.001|
| MRS 4–6                        | 109 (42.4%)           | 147 (57.5%)          |     |
| **DEATH**                      |                       |                      |     |
| In Hospital                    | 31 (66.3%)            | 24 (43.7%)           |     |
| 3 months                       | 81 (60.9%)            | 78 (49.1%)           | <0.001|

Yet another paramount finding noted was that of a lower ABG in diabetics as compared to non-diabetics (36 in Group A as compared to 103 in Group B).

The mean systolic blood pressures were 184.29 and 171.34 in the two groups respectively and diastolic pressures were 103.3 and 99.1 in Group A and Group B, respectively.

Median Glasgow Coma Scale was 11 in Group A and 12 in Group B (P ≤ 0.001). Median ICH score was 2 in Group A and 1 in Group B. Mean ABG value was 220.73 ± 57.23 mg/dl (160–407 mg/dl) in Group A and 124.37 ± 20.0 mg/dl (42–159 mg/dl) in Group B.

Confounding factors such as hematoma volume, presence of intraventricular extension, anatomical location, and GCS on arrival also seemed to affect the outcome of patients with SICH. In Group A, 141 patients had supratentorial hematomas with a mean volume of 31.54 ± 23.12 ml (5–110 ml), and 72 patients with a volume >30 ml. Thirty-one patients had infratentorial hematomas. One hundred nine patients had intraventricular extension (IVE), with 57 having imaging suggestive of hydrocephalus. Sixteen patients among these required an EVD and 45 patients underwent surgical evacuation of hematoma.

In Group B, 283 patients had supratentorial hematomas, with a mean volume of 19.5 ± 13.77 ml (3–70 ml) and 61 patients had a hematoma volume >30 ml. Thirty patients had infratentorial hematomas. One hundred twenty patients had intraventricular extension, with 68 patients having hydrocephalus on imaging. Nineteen patients had an EVD inserted and 39 patients underwent surgical evacuation of hematoma.

In terms of mean hematoma volumes, patients in Group A had mean hematoma volumes almost twice that of group B and 64% of patients in group A presented with IVE in comparison to 36% in group B. Pearson’s correlation of ABG with Volume of hematoma, GCS and IVE showed a strong correlation with p < 0.001 and R-values of 0.249, −0.267, and 0.261, respectively (Table 2).

### Outcome Assessment

Outcome mRS at 3 months was unavailable for 12 patients as they were lost to follow up. Telephonic mRS was obtained for 206 patients. Median mRS among the patients in Group A was 5, with 63 (36.6%) patients having an mRS of 0–3 and 109 (63.4%) with an mRS of 4–6. Thirty-one patients died in the hospital and another 50 within 90 days. In Group B, the median mRS was 4 at discharge and 3 at 90 days with 174 (54.2%) patients having good outcome and 147 (45.8%) with poor outcome at 3 months. Twenty-four patients died in the hospital and 54 in the first 3 months. Age, GCS, volume of hematoma, admission blood glucose, IVE and Hydrocephalus were significant predictors of mortality and poor outcome on univariate analysis with a p < 0.05 (Table 3).

### Multivariate Logistic Regression

Multivariate Logistic regression was performed to determine the relationship between the Age, GCS, Volume of hematoma, ABG, IVE, and presence of hydrocephalus with mortality and poor outcome (Table 4). It failed to demonstrate association between blood glucose and mortality (P = 0.249, 95% CI 0.948–1.006) and outcome (P = 0.538, 95% CI 0.997–1.005). Age, Volume of hematoma and GCS were stronger predictors of mortality and morbidity (Table 4).
**DISCUSSION**

Diabetes and high blood glucose are well-known risk factors for ischemic stroke (5, 27–29). While a number of ischemic studies showed worse outcomes with hyperglycaemia (7) others have shown protective effect of hyperglycaemia in small vessel disease (30). A number trials attempting to control hyperglycaemia in ischemic stroke patients have been negative (7, 31).

High blood glucose values have shown a strong association with higher mortality and morbidity in multiple cohorts, independent to the presence of Diabetes Mellitus (9, 14, 15, 17, 32, 33), while some others (8, 12, 23) have shown contrasting reports like ours. Two Meta-analysis have concluded that hyperglycaemia increases both short term and long term mortality in intracerebral hemorrhage (15, 16). However these included studies with subarachnoid hemorrhage also. A recent meta-analysis by Zheng et al. (34) in 2018, concluded that hyperglycaemia was associated with poor functional outcome in patients with ICH. The wide range of blood glucose levels and heterogeneity among studies could be a reason for bias in these meta-analyses. Random blood glucose has not been a predictor of mortality in Indian ICH studies (21, 22). However, the pool of available evidence pertaining to blood glucose variability and ICH is still limited (35–37).

Several animal studies have also identified an evident association between hyperglycaemia and perihematomal neuronal apoptosis in rat models (38). They also predicted that high blood glucose level was strongly associated with increased neurologic injury and decreased autophagy (39). This was attributed to a direct causal effect of hyperglycaemia, which enhances the synthesis of oxygen free radicals (super oxide) and also responsible for the down regulation of super-oxide dismutase. Superoxide, thus produced, induces the synthesis of tissue plasminogen activators thereby de-stabilizing the clot and causing hematoma expansion in ICH models via plasma kallikrein (40, 41). Decline of blood glucose within 72 h of ictus has also been correlated with reduction in hematoma expansion and poor clinical outcome (42).

In a multivariate analysis, ABG >8 mmol/L appeared to be a significant independent predictor of death within 2 days of stroke onset (43). In the 127 patients who died in a study by Fogelholm et al. mean blood glucose values were 9.1 mmol/L in comparison to 6.8 mmol/L among survivors with a p < 0.01 (11). Kimura et al. in their study of 100 patients also found that higher blood glucose values on presentation was directly associated with a higher mortality (glucose: death, 205 mg/dl vs. survival, 131 mg/dl, (p < 0.0001) (20). A similar observation was noticed in our study too with the mean blood glucose among patients who died in being 177.20 mg/dl compared to 150.17 in those who survived for 90 days (P < 0.001, 95% CI = 15.914–38.147) on univariate analysis.

Lee et al. (12) conducted a prospective study across 33 centers in Korea and concluded that admission glucose was an independent risk factor for early mortality in patients with diabetes and it was an independent risk factor for long term mortality (p = 0.09) in non-diabetics. Long term mortality in diabetics remained unaffected. Another study conducted by Passero et al. (10) in Italy, projected that elevated admission glucose in patients with ICH was an independent predictor of 3 day and 3 month mortality in non-diabetic, non-comatose patients after supratentorial ICH. In a large retrospective study from the China National Stroke Registry comprising of 2,951 patients, Sun et al. (17) concluded that elevated admission glucose level is an independent predictor of 90-day poor outcome, the prognostic value of which is greater in non-diabetics than diabetics. The likely cause for this difference was

---

**TABLE 3** | Univariate analysis for mortality and outcome.

| Parameter        | Mortality Alive | Mortality Dead | P      | 95% CI          | Poor outcome Good | Poor outcome Bad | P      | 95% CI          |
|------------------|-----------------|----------------|--------|-----------------|-------------------|------------------|--------|-----------------|
| Age (mean)       | 56.95 ± 11.84   | 61.54 ± 31.29  | <0.001 | 2.28 to 6.908   | 56.63 ± 11.87     | 60.12 ± 12.87   | 0.002  | –5.673 to –1.299 |
| GCS              | 12.11 ± 2.68    | 8.09 ± 3.67    | <0.001 | –4.587 to –3.445| 9.1 ± 3.61        | 12.64 ± 2.46   | <0.001 | 2.988 to 4.088  |
| Volume           | 17.59 ± 13.23   | 31.82 ± 22.18  | <0.001 | 11.095 to 17.359| 15 ± 11.32        | 28.89 ± 20.25  | <0.001 | –16.82 to –10.96|
| Blood glucose    | 150.17 ± 58.48  | 177.20 ± 59.29 | <0.001 | 15.914 to 38.147| 147.04 ± 55.41    | 169.86 ± 62.09 | <0.001 | –33.267 to –12.376 |
| IVE              | 127 (55%)       | 104 (45%)      | <0.001 | 81 (35.1%)      | 150 (64.9%)       | <0.001 | 87 (88.5%)      |
| Hydrocephalus    | 60 (47.2%)      | 67 (52.8%)     | <0.001 | 40 (31.5%)      |                   |                   |        |                 |

**TABLE 4** | Multiple logistic regression for mortality and poor outcome.

| Parameter        | Mortality Odds ratio | P      | 95% CI          | Poor Outcome Odds ratio | P      | 95% CI          |
|------------------|----------------------|--------|-----------------|-------------------------|--------|-----------------|
| Age              | 1.08                 | <0.001 | 1.030–1.083     | 1.050                   | <0.001 | 1.030–1.070     |
| GCS              | 0.721                | <0.001 | 0.663–0.783     | 0.730                   | <0.001 | 0.661–0.793     |
| Volume           | 1.029                | <0.001 | 1.013–1.045     | 1.051                   | <0.001 | 1.031–1.071     |
| Blood glucose    | 1.002                | 0.249  | 0.948–1.006     | 1.001                   | 0.538  | 0.997–1.006     |
| IVE              | 0.973                | 0.923  | 0.566–1.702     | 0.694                   | 0.166  | 0.413–1.164     |
| Hydrocephalus    | 0.650                | 0.172  | 0.351–1.206     | 0.915                   | 0.781  | 0.489–1.713     |
probably stress hyperglycemia, insulin resistance, undiagnosed diabetes and undertreatment. Our study too found diabetics to have a better control of glucose levels ($p = 0.005$).

The present study shows that elevated blood glucose at the time of SICH was associated with a more severe form of ICH, accounting for increased mortality and morbidity. Hyperglycaemia in the setting of acute neurological injury is attributed to a catecholamine surge and the generalized stress response (8). It is proposed that high blood glucose at admission contributes to poor outcome, due to exacerbation of cerebral edema and cerebral damage (44). Though several animal studies have shown that ICH promotes vasogenic oedema and perihematoma neuronal death, some authors have noticed that elevated ABG could only reflect the severity of the ICH as a stress reaction to a serious brain injury (39).

Multivariate logistic regression failed to uphold ABG as an independent predictor of mortality in our study when adjusted for age, GCS, and hematoma volume. The loss of significance of blood glucose in multivariate models may be due to confounding and possible statistical interaction by GCS, Age, and Hematoma volume. These are well known, established independent factors of poor outcome and mortality in ICH [Figure 2; (2, 45–48)]. This could be attributed to a stress response (49) following ICH as was seen in the Fogelholm study (11) of Finland and the Italian study of Passero et al. (10). Ntaios et al. (35) have pointed out in the realm of ischemic strokes that the relationship between admission glucose and outcomes may be J-shaped and best modeled by fractional polynomials. In light of complex relationships between glucose and outcomes and heterogeneity in neurological conditions, Kent et al. (50) questioned whether underlying assumptions of multivariate regression modeling are met.

Intensive blood glucose lowering with the use of insulin has failed to provide favorable outcomes in patients with ICH (51, 52) SAH (53) and ischemic stroke (54). A tight glycemic control may result in brain energy crisis which is associated with a high rate of mortality (55). When effective lowering of blood glucose in these studies have failed to improve outcome, it is unlikely that elevated blood glucose is the cause or effect of mortality in the different proposed mechanisms of increasing brain oedema and perihematoma cell death (18). It is probable that high ABG was associated with variables signifying the severity of stroke, such as blood pressure, hematoma volume, midline shift of the cerebral structures, intraventricular extension, and poor sensorium. Patients in Group A had larger volume bleeds, and patients with poorer GCS. This translated into far more deaths among patients in Group A and poorer clinical outcome thereafter. Whether the adverse effect of high blood glucose levels manifests through larger clot volumes needs to be further explored with newer technologies of continuous blood glucose monitoring (56, 57).

**CONCLUSION**

Admission blood glucose levels was not an independent predictor of mortality in our study when adjusted with age, GCS and hematoma volume. GCS and volume of hematoma were better predictors of mortality at 90 days while volume of hematoma and age were better predictors of functional outcome. Catastrophic SICH is associated with high ABG, which appears to be a stress response to the severity of bleeding. The effect of high blood glucose levels on SICH outcome is probably multifactorial and warrant further research.

**ETHICS STATEMENT**

This study was carried out in accordance and approval of the ethics committee of Manipal Academy of Higher Education vide approval no IEC 209/2015.

**AUTHOR CONTRIBUTIONS**

LK was the primary investigator involved in write up of the article. AH was involved in data collection, follow up of patients and tabulation of results. GM and RN were involved in review of article.
REFERENCES

1. Ariesen MJ, Claus SP, Rinkel GJE, Algra A. Risk factors for intracerebral hemorrhage in the general population: a systematic review. Stroke (2003) 34:2069. doi: 10.1161/01.STR.0000088667.09344.8D

2. Qureshi AI, Mendelow AD, Hanley DF. Intracerebral haemorrhage. Lancet (2009) 373:1632–44. doi: 10.1016/S0140-6736(09)60371-8

3. Bhalla A, Wang Y, Rudd A, Wolfe CDA. Differences in outcome and predictors between ischemic and intracerebral hemorrhage: the South London Stroke Register. Stroke (2013) 44:2174–81. doi: 10.1161/STROKEAHA.113.001263

4. Dennis MS. Outcome after brain haemorrhage. Cerebrovasc Dis. (2003) 16(Suppl. 1):9–13. doi: 10.1159/000069935

5. Mankovsky BN, Metzger BE, Molitch ME, Biller J. Cerebrovascular disorders in patients with diabetes mellitus. J Diabetes Complicat. (1996) 10:228–42. doi: 10.1016/S1056-8727(96)00006-9

6. Capes SE, Hunt D, Malmberg K, Pathak P, Gerstein HC. Stress hyperglycaemia and predictors between ischemic and intracerebral hemorrhage: a systematic overview. J Neurol Neurosurg Psychiatry. (2005) 76:349–53. doi: 10.1136/jnnp.2003.034819

7. Lee SH, Kim BJ, Bae HJ, Lee JS, Lee J, Park BJ, et al. Effects of glucose level on early and long-term mortality after intracerebral haemorrhage: the acute brain bleeding analysis study. Diabetologia (2010) 53:429–34. doi: 10.1007/s00125-010-1817-z

8. Bruno A, Levine SR, Frankel MR, Brodt TG, Lin Y, Tilley BC, et al. The deleterious effect of admission hyperglycemia on survival and functional outcomes from the randomized INSULINFARCT trial. Stroke (2014) 45:2343–9. doi: 10.1161/STROKEAHA.114.005805

9. Béjot Y, Aboa-Eboulé C, Hervieu M, Jacquin A, Osseby GV, Rouaud O, et al. Hyperglycemia exacerbates brain edema and perihematomal cell death after intracerebral hemorrhage. Neurocrit Care (2013) 19:1626–30. doi: 10.1007/s12028-013-9659-z

10. Stöllberger C, Exner I, Finsterer J, Slany J, Steger C. Stroke in patients with diabetes mellitus. Diabet Med Res Rev. (2001) 17:242–62. doi: 10.1002/sim.201

11. Bhatia R, Singh H, Singh S, Padma MV, Prasad K, Tripathi M, et al. Hyperglycemia promotes tissue plasminogen activator-induced hemorrhage by exacerbating intracerebral hemorrhage via the downregulation of aquaporin-4: temporal assessment with magnetic resonance imaging. Stroke (2013) 44:1682–9. doi: 10.1161/STROKEAHA.113.675983

12. Kongwad et al. Admission Blood Glucose Levels in SICH
increasing superoxide production. *Ann Neurol.* (2011) 70:583–90. doi: 10.1002/ana.22538

41. Liu J, Gao BB, Clermont AC, Blair P, Chilcote TJ, Sinha S, et al. Hyperglycemia-induced cerebral hematoma expansion is mediated by plasma kallikrein. *Nat Med.* (2011) 17:206–10. doi: 10.1038/nm.2295

42. Qureshi AI, Palesch YY, Martin R, Novitzke J, Cruz-Flores S, Ehtisham A, et al. Association of serum glucose concentrations during acute hospitalization with hematoma expansion, perihematomal edema, and three month outcome among patients with intracerebral hemorrhage. *Neurocrit Care* (2011) 15:428–35. doi: 10.1007/s12028-011-9541-8

43. Franke CL, Van Swieten JC, Algra A, van Gijn J. Prognostic factors in patients with intracerebral haematoma. *J Neurol Neurosurg Psychiatr.* (1992) 55:653–7. doi: 10.1136/jnnp.55.8.653

44. Chuang YC, Chen YM, Peng SK, Peng SY. Risk stratification for predicting 30-day mortality of intracerebral hemorrhage. *Int J Qual Health Care* (2009) 21:441–7. doi: 10.1093/intqhc/mzp041

45. Bilbao G, Garibi J, Pomposo I, Pijoan JI, Carrasco A, Catalán G, et al. A prospective study of a series of 356 patients with supratentorial spontaneous intracerebral haematomas treated in a Neurosurgical Department. *Acta Neurochirurgica* (2005) 147:823–9. doi: 10.1007/s00701-005-0531-5

46. Hemphill JC, Bonovich DC, Besmertis L, Manley GT, Johnston SC. The ICH Score. *Stroke* (2001) 32:891–7. doi: 10.1161/01.STR.32.4.891

47. Bhattathiri PS, Gregson B, Prasad KSM, Mendelow AD. Intraventricular hemorrhage and hydrocephalus after spontaneous intracerebral hemorrhage: results from the STICH trial. In: Hoff JT, Keep RF, Xi G, Hua Y. editors. *Brain Edema XIII. Acta Neurochirurgica Supplementum,* Vol. 96. Vienna: Springer, p. 65–68. doi: 10.1007/3-211-30714-1_16

48. Hallevi H, Dar NS, Barreto AD, Morales MM, Martin-Schild S, Abraham AT, et al. The IVH Score: a novel tool for estimating intraventricular hemorrhage volume: clinical and research implications. *Crit Care Med.* (2009) 37:969.e1–74. doi: 10.1097/01.CCM.0000201875.12245.6F

49. Melamed E. Reactive hyperglycaemia in patients with acute stroke. *J Neurol Sci.* (1976) 29:267–75.

50. Kent TA, Shah SD, Mandava P. Improving early clinical trial phase identification of promising therapeutics. *Neurology* (2015) 85:274–83. doi: 10.1212/WNL.0000000000001757

51. Godoy DA, Piñero GR, Svampa S, Papa F, Di Napoli M. Hyperglycemia and short-term outcome in patients with spontaneous intracerebral hemorrhage. *Neurocrit Care* (2008) 9:217–29. doi: 10.1007/s12028-008-9063-1

52. Vespa P, Boonyaputhikul R, McArthur DL, Miller C, Etchepare M, Bergsneider M, et al. Intensive insulin therapy reduces microdialysis glucose values without altering glucose utilization or improving the lactate/pyruvate ratio after traumatic brain injury. *Crit Care Med.* (2006) 34:850–6. doi: 10.1097/01.CCM.0000201875.12245.6F

53. Bilotta F, Spinelli A, Giovannini F, Delfinio A, Delfinio R, Rosa G. The effect of intensive insulin therapy on infection rate, vasospasm, neurologic outcome, and mortality in neurointensive care unit after intracranial aneurysm clipping in patients with acute subarachnoid hemorrhage: a randomized prospective pilot trial. *J Neurosurg Anesthesiol.* (2007) 19:156–60. doi: 10.1097/ANA.0b013e3180338e69

54. Gray CS, Hildreth AJ, Sandercoc PA, O’Connell JE, Johnston DE, Cartlidge NE, et al. Glucose-potassium-insulin infusions in the management of post-stroke hyperglycaemia: the UK Glucose Insulin in Stroke Trial (GIST-UK). *Lancet Neurol.* (2007) 6:397–406. doi: 10.1016/S1474-4422(07)70080-7

55. Oddo M, Schmidt JM, Carrera E, Badjiatia N, Connolly ES, Presciutti M, et al. Impact of tight glycemic control on cerebral glucose metabolism after severe brain injury: a microdialysis study. *Crit Care Med.* (2008) 36:3233–8. doi: 10.1097/01.CCM.000031818f04b26

56. Krinsley JS, Chase JG, Gunst J, Martensson J, Schultz MJ, Taconne FS, et al. Continuous glucose monitoring in the ICU: clinical considerations and consensus. *Crit Care* (2017) 21:197. doi: 10.1186/s13054-017-1784-0

57. Rostami E. Glucose and the injured brain-monitored in the neurointensive care unit. *Front Neurol.* (2014) 5:91. doi: 10.3389/fneur.2014.00091

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Kongwad, Hegde, Menon and Nair. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.